SCOPUS 정보 검색 플랫폼

Volumn 78, Issue 3, 1998, Pages 388-389

Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue

Author keywords

Deoxycytidine analogue; Flu like symptoms; Interleukin 6

Indexed keywords

CYTIDINE DERIVATIVE; DEOXYCYTIDINE; INTERLEUKIN 6;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; FEVER; FLU LIKE SYNDROME; HUMAN; LUNG NON SMALL CELL CANCER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031867660 PISSN: 00070920 EISSN: None Source Type: Journal
DOI: 10.1038/bjc.1998.504 Document Type: Article

Times cited : (7)

References (6)

1
- 0025978216
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
- Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raher MN and Plunkett W (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498
- (1991) J Clin Oncol , vol.9 , pp. 491-498
- Abbruzzese, J.L.¹ Grunewald, R.² Weeks, E.A.³ Gravel, D.⁴ Adams, T.⁵ Nowak, B.⁶ Mineishi, S.⁷ Tarassoff, P.⁸ Satterlee, W.⁹ Raher, M.N.¹⁰ Plunkett, W.¹¹

2
- 0027993707
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study
- Abralt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D and Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540
- (1994) J Clin Oncol , vol.12 , pp. 1535-1540
- Abralt, R.P.¹ Bezwoda, W.R.² Falkson, G.³ Goedhals, L.⁴ Hacking, D.⁵ Rugg, T.A.⁶

3
- 0028033227
- Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study
- Anderson H, Lund B, Bach F, Thatcher N, Walling J and Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826
- (1994) J Clin Oncol , vol.12 , pp. 1821-1826
- Anderson, H.¹ Lund, B.² Bach, F.³ Thatcher, N.⁴ Walling, J.⁵ Hansen, H.H.⁶

4
- 0030035730
- A phase I study of a 24-hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
- Anderson H, Thatcher N, Walling J and Hansen H (1996) A phase I study of a 24-hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74: 460-462
- (1996) Br J Cancer , vol.74 , pp. 460-462
- Anderson, H.¹ Thatcher, N.² Walling, J.³ Hansen, H.⁴

5
- 0028272277
- Phase I clinical trial of gemcitabine given as as intravenous bolus on 5 consecutive days
- O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee PG, Tarassoff PG and Von Hoff DD (1994) Phase I clinical trial of gemcitabine given as as intravenous bolus on 5 consecutive days. Eur J Cancer 30A: 417-418
- (1994) Eur J Cancer , vol.30 A , pp. 417-418
- O'Rourke, T.J.¹ Brown, T.D.² Havlin, K.³ Kuhn, J.G.⁴ Craig, J.B.⁵ Burris, H.A.⁶ Satterlee, P.G.⁷ Tarassoff, P.G.⁸ Von Hoff, D.D.⁹

6
- 0026441565
- Difluorodeoxycytidine (dFdC) - Gemcitabine: A phase I study
- Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M and Baker L (1992) Difluorodeoxycytidine (dFdC) - gemcitabine: a phase I study. Invest New Drugs 10: 165-170
- (1992) Invest New Drugs , vol.10 , pp. 165-170
- Poplin, E.A.¹ Corbett, T.² Flaherty, L.³ Tarasoff, P.⁴ Redman, B.G.⁵ Valdivieso, M.⁶ Baker, L.⁷

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.